224.91

0.48% 1.06

Cardinal Health Inc (CAH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Cardinal Health Inc stock is traded at $224.91, with a volume of 535.80K. It is up +0.48% in the last 24 hours and up +15.22% over the past month. Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Previous Close:

$223.85

Open:

$222.78

24h Volume:

535.80K

Relative Volume:

0.26

Market Cap:

$52.70B

Revenue:

$250.74B

Net Income/Loss:

$1.55B

P/E Ratio:

34.39

EPS:

6.5398

Net Cash Flow:

$4.39B

1W Performance:

+9.99%

1M Performance:

+15.22%

6M Performance:

+12.48%

1Y Performance:

+39.35%

1-Day Range:

$221.03

$225.27

1-Week Range:

$202.04

$225.27

52-Week Range:

$137.75

$233.60

Cardinal Health Inc Stock (CAH) Company Profile

Name

Cardinal Health Inc

Sector

Healthcare (1112)

Industry

Medical Distribution (11)

Phone

(614) 757-3033

Address

7000 CARDINAL PLACE, DUBLIN, OH

Employee

57,700

Twitter

@cardinalhealth

Next Earnings Date

2026-04-30

Latest SEC Filings

CAH's Discussions on Twitter

Compare CAH vs MCK, COR, HSIC, AHG

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAH Cardinal Health Inc	225.00	52.43B	250.74B	1.55B	4.39B	6.5398
MCK Mckesson Corp	778.37	94.25B	403.43B	5.10B	5.41B	38.47
COR Cencora Inc	279.73	54.80B	328.68B	2.55B	1.56B	13.03
HSIC Henry Schein Inc	81.47	9.26B	13.38B	418.00M	391.00M	3.3112
AHG Akso Health Group Adr	1.32	1.15B	14.85M	-136.07M	7.25M	-0.4726

Cardinal Health Inc Stock (CAH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-09-26	Upgrade	Citigroup	Neutral → Buy
Dec-09-25	Initiated	Barclays	Overweight
Jun-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-05-25	Upgrade	Jefferies	Hold → Buy
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Jan-07-25	Upgrade	Evercore ISI	In-line → Outperform
Jan-06-25	Upgrade	BofA Securities	Neutral → Buy
Dec-13-24	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-04-24	Resumed	Mizuho	Outperform
Feb-26-24	Initiated	Leerink Partners	Outperform
Feb-09-24	Upgrade	Argus	Hold → Buy
Jan-03-24	Initiated	Barclays	Overweight
Dec-14-23	Initiated	Wells Fargo	Underweight
Jul-10-23	Downgrade	Evercore ISI	Outperform → In-line
Mar-31-23	Initiated	Citigroup	Neutral
Feb-03-23	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-04-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-22-22	Resumed	Morgan Stanley	Overweight
May-26-22	Downgrade	Barclays	Overweight → Equal Weight
May-18-22	Upgrade	Evercore ISI	In-line → Outperform
Apr-12-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-01-22	Resumed	Credit Suisse	Neutral
Aug-06-21	Downgrade	Deutsche Bank	Buy → Hold
Aug-05-21	Downgrade	BofA Securities	Buy → Underperform
May-10-21	Downgrade	Robert W. Baird	Outperform → Neutral
Jan-08-21	Upgrade	Wolfe Research	Underperform → Peer Perform
Nov-02-20	Upgrade	Barclays	Equal Weight → Overweight
Sep-25-20	Upgrade	Deutsche Bank	Hold → Buy
Jul-20-20	Upgrade	Guggenheim	Neutral → Buy
May-15-20	Upgrade	UBS	Neutral → Buy
Apr-23-20	Resumed	Credit Suisse	Neutral
Mar-20-20	Upgrade	BofA/Merrill	Underperform → Buy
Feb-12-20	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-07-20	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-16-19	Downgrade	Guggenheim	Buy → Neutral
Sep-12-19	Initiated	Deutsche Bank	Hold
Aug-27-19	Downgrade	Argus	Buy → Hold
Aug-20-19	Upgrade	Guggenheim	Neutral → Buy
Apr-18-19	Initiated	Guggenheim	Neutral
Jan-17-19	Initiated	UBS	Neutral
Nov-16-18	Downgrade	Leerink Partners	Outperform → Mkt Perform
Apr-24-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
Apr-02-18	Upgrade	Argus	Hold → Buy
Mar-08-18	Initiated	Barclays	Equal Weight
Feb-27-18	Resumed	BofA/Merrill	Underperform
Jan-05-18	Initiated	Evercore ISI	In-line

View All

Cardinal Health Inc Stock (CAH) Latest News

Jun 14, 2026

Cardinal Health Inc. Stock (US14149Y1082): Insider and institutional ownership moves in focus - AD HOC NEWS

Jun 14, 2026

Jun 13, 2026

Cardinal Health Inc. Stock (US14149Y1082): Ownership shift puts hospital-at-home strategy in focus - AD HOC NEWS

Jun 13, 2026

Jun 12, 2026

Cardinal Health (CAH) Edges Higher as Healthcare Distribution Giant Hests Above Key SupportPCR Extreme - newsline.com

Jun 12, 2026

Cardinal Health Inc. stock outperforms competitors on strong trading day - MarketWatch

Jun 12, 2026

Cardinal Health Inc. Stock (US14149Y1082): Valuation in focus after recent gains - AD HOC NEWS

Jun 12, 2026

Is Cardinal Health (CAH) Stock Undervalued Right Now? - Yahoo Finance Australia

Jun 12, 2026

William O'Neil Initiates Cardinal Health at Buy - Moomoo

Jun 12, 2026

Cardinal Health Inc. Stock (US14149Y1082): valuation focus as shares hover near recent highs - AD HOC NEWS

Jun 12, 2026

Jun 11, 2026

Barclays Keeps Their Buy Rating on Cardinal Health (CAH) - The Globe and Mail

Jun 11, 2026

Cardinal Health Stock: Does It Diversify Your Portfolio Or Just Double Down On Market Risk? - Trefis

Jun 11, 2026

Jun 10, 2026

Elinor Riggs Joins Cardinal Health as SVP, CIO & CTO, Pharmaceutical & Specialty Solutions - hrtoday.in

Jun 10, 2026

Barclays Maintains Cardinal Health(CAH.US) With Buy Rating, Maintains Target Price $258 - Moomoo

Jun 10, 2026

Jun 09, 2026